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Background: In fibrotic lung diseases, expression of caveolin-1 is decreased in fibroblasts and monocytes. The
effects of this deficiency are reversed by treating cells or animals with the caveolin-1 scaffolding domain peptide
(CSD, amino acids 82–101 of caveolin-1) which compensates for the lack of caveolin-1. Here we compare the
function of CSD subdomains (Cav-A, Cav-B, Cav-C, Cav-AB, and Cav-BC) and mutated versions of CSD (F92A and
T90A/T91A/F92A).
Methods: Migration toward the chemokine CXCL12 and the associated expression of F-actin, CXCR4, and pSmad
2/3 were studied in monocytes from healthy donors and SSc patients. Fibrocyte differentiation was studied using
PBMC from healthy donors and SSc patients. Collagen I secretion and signaling were studied in fibroblasts derived
from the lung tissue of healthy subjects and SSc patients.
Results: Cav-BC and CSD at concentrations as low as 0.01 μM inhibited the hypermigration of SSc monocytes and
TGFβ-activated Normal monocytes and the differentiation into fibrocytes of SSc and Normal monocytes. While CSD
also inhibited the migration of poorly migrating Normal monocytes, Cav-A (and other subdomains to a lesser
extent) promoted the migration of Normal monocytes while inhibiting the hypermigration of TGFβ-activated
Normal monocytes. The effects of versions of CSD on migration may be mediated in part via their effects on
CXCR4, F-actin, and pSmad 2/3 expression. Cav-BC was as effective as CSD in inhibiting fibroblast collagen I and
ASMA expression and MEK/ERK signaling. Cav-C and Cav-AB also inhibited collagen I expression, but in many cases
did not affect ASMA or MEK/ERK. Cav-A increased collagen I expression in scleroderma lung fibroblasts. Full effects
on fibroblasts of versions of CSD required 5 μM peptide.
Conclusions: Cav-BC retains most of the anti-fibrotic functions of CSD; Cav-A exhibits certain pro-fibrotic functions.
Results obtained with subdomains and mutated versions of CSD further suggest that the critical functional residues
in CSD depend on the cell type and readout being studied. Monocytes may be more sensitive to versions of CSD
than fibroblasts and endothelial cells because the baseline level of caveolin-1 in monocytes is much lower than in
these other cell types.
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Caveolin-1, a protein associated with plasma membrane
invaginations known as caveolae and with other cellular
membranes, is a promising therapeutic target in ILDs.
We and others have shown that caveolin-1 is deficient in
the lung tissue of SSc and IPF patients and in cells iso-
lated from the lung tissue and blood of these patients in-
cluding fibroblasts, monocytes, and neutrophils [1-3].
Similarly, caveolin-1 is also deficient in mice in which
ILD has been induced with bleomycin or irradiation
[2,3].
Caveolin-1 binds to and thereby inhibits the function
of kinases in several major families including PKC,
MAPK, Src, and G protein [4-7] and regulates signaling
and cell functions induced by the major pro-fibrotic
cytokine, TGFβ [1,8,9]. The effects of caveolin-1 de-
ficiency in cells and in animals can be reversed either
by using adenovirus encoding full-length caveolin-1 or
using the caveolin-1 scaffolding domain peptide (CSD;
amino acids 82–101 of caveolin-1) [1,2]. When CSD is
synthesized in fusion with the Antennapedia Internaliza-
tion Sequence, it can enter cells and inhibit kinases just
like full-length caveolin-1 [10,11]. CSD was reported [4]
to bind to target kinases through consensus sequences
(ΦXΦXXXXΦ and ΦXXXXΦXXΦ) where Φ stands for
any of the aromatic amino acids (F, W, or Y) and X
stands for any amino acid. Later studies suggested that
the initial definition of the consensus sequences was
overly stringent and that the consensus sequences for
caveolin binding domains (CBDs) are ΦXZXXXXΦ
and ZXXXXΦXXZ where Z stands for F, W, Y, I, V,
or L [12].
Given the large number of signaling molecules that
contain CBDs and the heterogeneity of the primary
sequences of these CBDs, it is extremely likely that
subdomains of CSD will differ from each other and from
CSD in their ability to regulate the activity of these ki-
nases and therefore will have distinctive effects on cell
behavior. Indeed, previous studies on CSD subdomains
have given distinct results depending on the peptide be-
ing studied. For example, in experiments using endothe-
lial cells, amino acids 89–95, 82–95, and 89–101 all
inhibited eNOS production and it was therefore con-
cluded that 89–95 was the key sequence involved in this
process [11,13]. In contrast, 86–101, but not 88–101,
inhibited the activity of PKC isoforms purified from
transfected H5 insect cells [5]. Similarly, CSD, but not
84–92 or 93–101, inhibited the activity of MEK and
ERK purified from bacterial extracts [14].
In order to identify CSD subdomains that may be
more useful than full-length CSD in treating human dis-
eases, here we have compared the ability of CSD and
several subdomains and mutated versions (each attached
to the Antennapedia Internalization Sequence) to reverseeffects associated with low caveolin-1 on the behavior of
monocytes (migration toward CXCL12; expression of
CXCR4 and F-actin and Smad 2/3 activation; differenti-
ation into fibrocytes) and fibroblasts (collagen I and
ASMA expression, MEK/ERK activation). For these exper-
iments, cells were isolated from both normal subjects and
scleroderma patients. Overall, the Cav-BC peptide (amino
acids 89–101) was as effective as, and sometimes more
effective than, full-length CSD. Interestingly, the Cav-A
peptide (amino acids 82–88) in some cases exacerbated
effects associated with low caveolin-1. While not surpris-
ing, it is noteworthy that the patterns of relative activity
that we observed with CSD subdomains and with mutated
versions of CSD differed from those obtained in a study of
CSD regulation of eNOS-mediated NO release in endo-
thelial cells [11].
Methods
Subjects for monocyte studies
Under a protocol approved by the Institutional Review
Board for Human Research for a Rheumatology Re-
search Repository, patients with SSc-ILD were recruited
from the Scleroderma Clinic at the Medical University
of South Carolina (MUSC). All patients fulfilled the Ameri-
can College of Rheumatology (formerly the American
Rheumatism Association, ARA) criteria for SSc [15] and
had evidence of SSc-ILD as previously defined [16]. Demo-
graphic data for SSc patients and normal healthy donors
are summarized in Table 1.
Monocyte isolation
Monocytes were isolated by standard methods [16,17].
Following centrifugation on density 1.083 Histopaque
cushions, monocytes were enriched by immunodep-
letion using a Dynal Monocyte Negative Isolation Kit
(Invitrogen, Carlsbad, CA) resulting in a cell popula-
tion about 95% Mac-1+ monocytes.
Monocyte migration
Assays were performed as previously described [17].
Briefly, CXCL12 (100 ng/ml in RPMI 1640 with 1% BSA)
was placed into the lower wells of Neuro Probe Multiwell
Chemotaxis Chambers (Neuro Probe, Gaithersburg, MD)
fitted with 5-μm pore size polycarbonate filters. 25 μl of
cell suspension (1 × 106 cells/ml) with or without TGFβ
pretreatment (45 min, 10 ng/ml in RPMI 1640 with 1%
BSA) was placed in the upper wells. Peptides were added
to cells before they were placed in the upper chamber.
After incubation for 2.5 h at 37°C in a 5% CO2 incubator,
filters were removed, fixed, and stained with DAPI
(Invitrogen, Carlsbad, CA). Cells on the underside of the
membrane were photographed and counted in six high
power fields per filter.
Table 1 Clinical features of SSc patients involved in
monocyte experiments
Race/Smoking Gender Patients Controls
Caucasian M 2 9
Caucasian F 7 12
African-American M 3 2
African-American F 3 9
Asian F 0 1
Smoker 0 2
Former Smoker 2 3
Age: Mean ± SD (range) Patients 52.3 ± 12.8 (27–79)
Controls 43.0 ± 11.9 (18–64)
Disease Limited Cutaneous 3
Diffuse Cutaneous 9
Overlap 3
Disease duration: Mean ± SD (range), yr 4.3 ± 2.8 (1-10)
Pulmonary Involvement (ILD) 15/15 (100%)
Pulmonary HTN 3/15 (20%)
GI Involvement 15/15 (100%)
Cardiac Involvement 2/15 (13.3%)
Renal Involvement 1/15 (6.7%)
Autoantibodies: ANA+ 15/15 (100%)
Scl-70+ 6/15 (40%)
Anti-centromere 1/15 (6.7%)
Table 2 Clinical features of autopsy samples used in
fibroblast experiments
Race/Smoking Gender Patients Controls
Caucasian M 0 1
Caucasian F 4 2
African-American M 0 0
African-American F 1 0
Smoker 1 0
Former Smoker 1 1
Age: Mean ± SD (range) Patients 46.6 ± 17.4 (21-62)
Controls 56.6 ± 8.5 (46-65)
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Were evaluated by immunocytochemistry in monocytes
that were isolated as described above, cultured overnight
in 6-well plates (1 × 105 cells per well) on coverslips in
RPMI 1640/ 20% FCS, and sequentially treated with
RPMI 1640/ 1% BSA with or without 10 ng/ml TGFβ,
then with the same medium containing 5 μM of the in-
dicated peptides as previously described [16]. Cells were
then fixed, labeled with FITC phalloidin (Sigma-Aldrich),
rabbit anti-CXCR4 (Santa Cruz Biotechnology sc-9046),
rabbit anti pSmad 2/3 (Cell Signaling 3102) Alexa Fluor®
555-conjugated secondary antibodies (Invitrogen), and
counterstained with the nuclear stain DAPI. Staining
was quantified in arbitrary units by image analysis of ten
cells in each category in terms of the average fluo-
rescence intensity ± s.e.m.Disease: Limited Cutaneous 4
Diffuse Cutaneous 1
Overlap 0
Pulmonary Involvement (ILD) 5/5 (100%)
GI Involvement 4/5 (80%)
Cardiac Involvement 4/5 (80%)
Renal Involvement 1/5 (20%)Smad western blots
Monocytes (2 × 106 cells per well) incubated as described
above for pSmad 2/3 immunocytochemistry were next
washed twice with PBS, then extracted with SDS-PAGE
sample buffer. Smad 2/3 and pSmad 2/3 levels were de-
termined by Western blotting using rabbit anti-Smad
2/3 (Cell Signaling 3102), rabbit anti-pSmad 2/3 (CellSignaling 3101), and mouse monoclonal anti-GAPDH
(EMD Millipore MAB374, clone 6C5) as a loading
control.
Monocyte to fibrocyte differentiation
Total PBMC from 40 ml of peripheral blood were plated
in eight wells of fibronectin-coated six-well plates in
DMEM/ 20% FCS with supplements for 12 days [18].
Medium was changed on day 5. Peptides were added on
day 2 and again on day 5 after the medium was changed.
Specific peptides used are described in the Figure
Legends. Images were acquired on day 12 and fibrocytes
were quantified in terms of elongated cells per 10 × field,
all of which were collagen I+. For immunocytochemistry,
the same methods were used except that the wells
contained coverslips.
Subjects for fibroblast studies
Fibroblasts were derived from lung tissue obtained at
autopsy from SSc patients (SLF) and from normal sub-
jects (NLF) and cultured as previously described [7].
Cells were used in passages 2–4. SSc lung tissue was
obtained from the Division of Pathology and Laboratory
Medicine at the Medical University of South Carolina
(MUSC). These SSc patients fulfilled the criteria of
American College of Rheumatology for the diagnosis of
SSc with lung involvement. Normal human lung tissue
was obtained from the Brain and Tissue Bank for De-
velopmental Disorders (Baltimore, MD) or from the
National Disease Research Interchange (Philadelphia,
Figure 1 (See legend on next page.)
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Figure 1 Effects of CSD and TGFβ on monocyte migration do not involve cell death/apoptosis. (A) Cell death/apoptosis was evaluated by
flow cytometry using Molecular Probes kit V13241. Briefly, cells were treated with CSD, TGFβ, or both reagents (see Methods). Cells were then
incubated with propidium iodide (PI) and fluorescent annexin V and analyzed by flow cytometry. Gates were set using unstained cells. A typical
experiment is shown in which live cells (PI-negative) were gated from dead cells (PI-positive) indicated as Live/Dead. Live cells were further gated
into apoptotic cells (annexin V-positive) and non-apoptotic cells (annexin V-negative) indicated as Annexin V: Minus/Plus. To validate the assay,
the indicated cells were treated with 20 mM H2O2 (a known inducer of cell death/apoptosis). (B) Apoptosis was evaluated by TUNEL labeling
using the In Situ Cell Death Detection Kit, Fluorescein (Product No. 11684795910, Roche, Indianapolis, IN). Briefly, cells on coverslips were treated
with CSD, TGFβ, or both reagents (see Methods); fixed; permeabilized; DNA strand breaks fluorescently labeled using TUNEL reagent; and imaged
by fluorescent microscopy. A typical experiment is shown in which essentially no cells were labeled except when permeabilized cells were
treated with DNase prior to TUNEL labeling. Nuclei were counter-stained using DAPI. (C) Flow cytometry quantification. Average values ± s.e.m.
are presented summarizing the results of four independent experiments performed using cells from different subjects. PI + indicates the
percentage of dead PI-positive cells; Annexin V + indicates the percentage of the PI-negative cell population that is annexin V-positive (i.e. apoptotic).
(D) TUNEL quantification. Three independent experiments were performed using cells from different subjects. The percentage of fluorescent,
TUNEL-positive cells was always < 2% except when DNA strand breaks were generated using DNase.
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Board for Human Subject Research at the MUSC as
non-human research. The demographics of these sub-
jects are provided in Table 2.
Fibroblast collagen I secretion and signaling
As previously described [8], aliquots of culture medium
or of cell layer, representing material derived from the
same number of cells, was probed on Western blots
using the following primary antibodies and appropriate
secondary antibodies: rabbit antibodies against ERK 1/2
(9102), pERK 1/2 (9106), MEK 1/2 (9122), and pMEK
1/2 (9121) from Cell Signaling (Beverly, MA); mouse
monoclonal anti-ASMA (A2547, clone 1A4) from Sigma
(Saint Louis, MO), and mouse monoclonal anti-actin
(MAB1501) from Millipore (Temecula, CA) and goat
anti-collagen I (AB758) from Millipore.
Fibroblast immunocytochemistry
NLF and SLF were cultured on coverslips and stained as
previously described [2,7] using the ASMA and pERK
antibodies indicated above and appropriate secondary
antibodies tagged with Alexa Fluor® 488. Nuclei were
stained with DAPI. Images were acquired using a Zeiss
510SML Laser Confocal Microscope (excitation S490/20,
emission D528/38) fitted with an oil-immersion ob-
jective (40 × /1.4).
Peptides
To compare the activity of CSD (amino acids 82–101 of
caveolin-1) to its subdomains, CSD and five subdomains
named by Bernatchez et al. [11] [ Cav-A (aa 82–88),
Cav-B (aa 89–95), Cav-C (aa 96–101), Cav-AB (aa 82–95)
and Cav-BC (aa 89–101)] were synthesized in fusion
with the Antennapedia Internalization Sequence. We
routinely refer to these fusions simply as CSD, Cav-A,
Cav-B, Cav-C, Cav-AB, and Cav-BC. The Antennapedia
Internalization Sequence alone was routinely used as
Control peptide, when tested scrambled CSD gavesimilar results to the Antennapedia Internalization Se-
quence alone. In addition, mutated CSD peptides in
which F92 was converted to A and in which T90, T91,
and F92 were all converted to A (referred to respectively
as 92A and 90-92A) were synthesized. CSD, Cav-A, Cav-B,
Cav-C, Cav-AB, Cav-BC, 92A, 90-92A, and control pep-
tides were dissolved at 10 mM in 100% DMSO, diluted
10-fold with water as previously described, and further
diluted as appropriate for each experiment [2,11,16,17].
Statistical analyses
Immunoreactive bands were quantified by densitometry
using ImageJ 1.32 NIH software. Raw densitometric data
were processed and analyzed using Prism 3.0 (GraphPad
Software Inc.). Student’s t-test was used to evaluate data.
In all Figures, *** indicates p < 0.001, ** indicates p < 0.01,
and * indicates p < 0.05.
Results
CSD and its subdomains differ in their ability to inhibit
the migration of normal and SSc monocytes
We previously demonstrated that SSc monocytes and
TGFβ-treated normal monocytes are hypermigratory to-
ward the CXCR4 ligand CXCL12 and that this migration
is inhibited by CSD [17]. To evaluate the possible role of
regulation of cell death and/or apoptosis by TGFβ or
CSD in their effects on migration, we studied cell death
(measured by propidium iodide staining) and apoptosis
(measured in terms of cell surface annexin V labeling).
We found that neither TGFβ nor CSD affected either
cell death or apoptosis even though in a positive control
experiment validating the method, H2O2 (a known in-
ducer of cell death and apoptosis) did have the expected
effects (Figure 1A,C). To further validate these observa-
tions, apoptosis was also evaluated by TUNEL labeling.
Again, essentially no apoptosis was observed in control
cells or in cells treated with CSD, TGFβ, or both re-
agents even though in a positive control TUNEL label-
ing was observed (Figure 1B,D). These observations
Figure 2 Effects of CSD and its subdomains on Normal and SSc monocyte migration in vitro. Normal monocytes (A) were isolated from
healthy donors, SSc monocytes (C) were isolated from SSc patients. The migration of these cells and Normal monocytes pretreated with TGFβ
(B) toward CXCL12 was quantified in the presence of 5 μM of CSD or the indicated subdomains of CSD as described in the Methods. The
Antennapedia Internalization Sequence alone was routinely used as the Control peptide; when tested scrambled CSD attached to the
Antennapedia Internalization Sequence gave similar results. Each symbol represents the results obtained with cells from an individual donor.
Reese et al. Respiratory Research 2013, 14:90 Page 6 of 18
http://respiratory-research.com/content/14/1/90strongly suggest that the effects of CSD and TGFβ on
migration are not mediated via effects on cell death or
apoptosis.
When we examined the effect of CSD subdomains on
the migration of normal monocytes, we found that while
all peptides used at the standard concentration of 5 μMTable 3 Quantification and statistical significance of monocyt
Monocytes Peptide Migration Statistical signi
Normal Control 20.1 ± 2.5
Normal CSD 12.6 ± 2.1 p < 0.05 vs Norma
Normal Cav-A 48.4 ± 7.8 p < 0.01 vs Norma
Normal Cav-B 35.4 ± 4.5 p < 0.01 vs Norma
Normal Cav-C 27.1 ± 2.1
Normal Cav-AB 37.8 ± 8.7 p < 0.05 vs Norma
Normal Cav-BC 32.6 ± 5.1 p < 0.05 vs Norma
Normal + TGFβ Control 99.9 ± 11.7 p < 0.001 vs Norm
Normal + TGFβ CSD 18.7 ± 4.5 p < 0.01 vs Normal + T
Normal + TGFβ Cav-A 47.4 ± 5.5 p < 0.01 vs Normal + T
Normal + TGFβ Cav-B 47.6 ± 4.4 p < 0.01 vs Normal + T
Normal + TGFβ Cav-C 36.2 ± 3.0 p < 0.01 vs Normal + T
Normal + TGFβ Cav-AB 37.7 ± 3.5 p < 0.01 vs Normal + T
Normal + TGFβ Cav-BC 25.9 ± 5.7 p < 0.01 vs Normal + T
SSc Control 303 ± 32 p < 0.001 vs Norm
SSc CSD 77 ± 10 p < 0.01 vs SSc/
SSc Cav-A 334 ± 44
SSc Cav-B Not Done
SSc Cav-C Not Done
SSc Cav-AB Not Done
SSc Cav-BC 138 ± 24 p < 0.02 vs SSc/
Data from Figure 2 (migration) and Figure 3 (image analyses of pSmad 2/3 staining
the indicated comparisons were determined using Students’ t test.[2,10,11,16,17] inhibited TGFβ-induced hypermigration,
only CSD inhibited the low level of migration observed
in the absence of TGFβ (Figure 2). Indeed, other
peptides, especially Cav-A, appeared to increase this
background migration (Figure 2, Table 3). While the
hypermigration of SSc monocytes was similar to thee migration and pSmad 2/3 staining data
ficance pSmad 2/3 Statistical significance
26.3 ± 1.1
l/Control 16.4 ± 0.5 p < 0.01 vs Normal/Control
l/Control 31.0 ± 1.1 p < 0.05 vs Normal/Control
l/Control 16.6 ± 1.6 p < 0.01 vs Normal/Control
19.1 ± 1.5 p < 0.01 vs Normal/Control
l/Control 26.8 ± 1.4
l/Control 18.4 ± 1.2 p < 0.01 vs Normal/Control
al/Control 43.1 ± 0.9 p < 0.01 vs Normal/Control
GFβ/Control 21.2 ± 1.2 p < 0.01 vs Normal + TGFβ/Control
GFβ/Control 37.7 ± 1.2
GFβ/Control 40.7 ± 1.2
GFβ/Control 43.0 ± 1.1
GFβ/Control 39.0 ± 1.5
GFβ/Control 18.7 ± 1.4 p < 0.01 vs Normal + TGFβ/Control
al/Control 54.1 ± 1.0 p < 0.01 vs Normal/Control





Control 36.6 ± 1.4 p < 0.01 vs SSc/Control
) are presented in terms of average value ± s.e.m. The statistical significance of
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were inhibited by CSD and Cav-BC, they differed dra-
matically in their response to Cav-A which inhibited
TGFβ-induced monocyte hypermigration but slightly in-
creased SSc monocyte hypermigration (Figure 2, Table 3).
Cav-B, Cav-C, and Cav-AB also inhibited TGFβ-inducedFigure 3 Effects of CSD and its subdomains on pSmad 2/3 expression
Methods, monocytes were isolated, plated on coverslips, treated with the i
pSmad 2/3 and with the nuclear stain DAPI. Representative images are sho
category. (A) Normal monocytes treated with TGFβ and CSD; (B) SSc mono
treated with TGFβ and CSD subdomains. The Antennapedia Internalization
tested scrambled CSD attached to the Antennapedia Internalization Sequemonocyte hypermigration, although not as effectively as
CSD and Cav-BC (Figure 2, Table 3).
Because TGFβ enhanced monocyte migration and this
effect was inhibited by CSD and each subdomain, we ex-
amined the effect of CSD and its subdomains on canon-
ical TGFβ signaling via the activation of Smad 2/3.in normal, TGFβ-treated, and SSc monocytes. As described in the
ndicated reagents (TGFβ, CSD, or its subdomains), fixed, and stained for
wn selected from 20 to 60 cells observed from four donors in each
cytes treated with CSD and its subdomains; (C) Normal monocytes
Sequence alone was routinely used as the Control peptide; when
nce gave similar results.
Figure 4 Smad 2/3 expression and activation in monocytes. The
indicated monocytes were isolated and treated with CSD (or control
peptide) as described in the Methods (Smad Western blots). TGFβ
indicates TGFβ-treated Normal monocytes. Smad 2/3 expression
and activation (i.e. pSmad 2/3 levels) were evaluated by Western
blotting (50 μg total protein per lane). The data shown are the
average ± s.e.m. in arbitrary units of the densitometric quantification
of three independent experiments with cells from different subjects.
The levels of Smad 2/3 and pSmad 2/3 in Normal monocytes
treated with control peptide (normalized against the GAPDH loading
control) were set to 100 arbitrary units. Indications of statistical
significance for TGFβ-treated Normal monocytes and SSc monocytes
are versus Normal monocytes. The indication of statistical
significance for TGFβ-treated Normal monocytes treated with CSD is
versus TGFβ-treated Normal monocytes treated with
control peptide.
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(i.e. pSmad 2/3) levels in monocytes showed a strong
correlation between ability to migrate and pSmad 2/3
levels under several conditions (Figure 3, quantified in
Table 3). For example, the enhanced ability of TGFβ-
treated normal monocytes and SSc monocytes to mi-
grate is accompanied by an increase in pSmad 2/3 levels.
The abilities of CSD and Cav-BC to strongly inhibit the
migration of TGFβ-treated normal monocytes and SSc
monocytes are accompanied by a major decrease in
pSmad 2/3 levels. The activation of Normal monocyte
migration by Cav-A is accompanied by an increase in
pSmad 2/3 level. On the other hand, various CSD
subdomains enhance the migration of Normal mono-
cytes or inhibit the migration of TGFβ-treated normal
monocytes while having no effect or an opposite effect
on pSmad 2/3 level. In summary, these studies demon-
strate that while CSD and its subdomains can affect
TGFβ signaling through pSmad 2/3, it is likely that both
their effects on TGFβ signaling and their well-known
effects on other signaling cascades together regulate mo-
nocyte migration.
To further validate these results, select experiments
were repeated and analyzed by Western blot (Figure 4).
In accord with the immunocytochemical data, the pSmad
2/3 level was much higher in SSc monocytes than in Nor-
mal monocytes. Interestingly, the Smad 2/3 level was in-
creased to an even greater extent than the pSmad 2/3
level in SSc monocytes (p < 0.001), suggesting that the in-
crease in pSmad 2/3 is driven by the increase in Smad 2/3.
Also in accord with the immunocytochemical data, the
pSmad 2/3 level in Normal monocytes was increased by
TGFβ treatment and this increase was substantially
blocked by CSD. In this case, the increase in pSmad 2/3
level occurred in the absence of any change in Smad 2/3
level.
CSD and its subdomains differ in their effects on CXCR4
expression and F-actin staining in normal and SSc
monocytes
To evaluate the mechanisms underlying the differential
effects of CSD and its subdomains on migration, we
compared the effects of these peptides on the expression
of CXCR4 and F-actin. Treatment of monocytes from
healthy donors with TGFβ significantly increased CXCR4
expression and this increase was completely inhibited by
CSD (Figure 5A, Table 3). In contrast, TGFβ only slightly
increased F-actin staining (Figure 5A) and this increase
was not fully reversed by CSD. When other peptides were
examined (Figure 5B, Table 3), the results were more com-
plicated because, in many cases, the peptide affected
CXCR4 and F-actin expression in the absence of TGFβ.
Cav-A, Cav-B, Cav-C, and to a lesser extent Cav-AB pro-
moted F-actin staining and this effect was decreased byTGFβ. Cav-BC, like CSD, had little effect on F-actin stai-
ning. Cav-A, and to a lesser extent Cav-B and Cav-C, in-
creased CXCR4 expression in normal cells while each
peptide inhibited CXCR4 expression similarly in TGFβ-
treated cells (Figure 5B, Table 3).
Experiments using SSc monocytes revealed a much
higher level of CXCR4 expression [16] and F-actin stain-
ing than in normal monocytes and a somewhat different
pattern of sensitivity to caveolin-1 peptides (Figure 6,
Table 3). As previously shown, CSD inhibited CXCR4
expression. Cav-BC also inhibited CXCR4 expression as
did Cav-B, Cav-C, and Cav-AB to a lesser extent. In con-
trast, as in healthy monocytes, Cav-A increased CXCR4
expression (Figure 6). CSD treatment also inhibited F-
actin staining. In addition, the effect of CSD on the cyto-
skeleton results in smaller cells. Cav-B and Cav-AB and
to a lesser extent Cav-C and Cav-BC somewhat inhibited
F-actin staining.
In summary, for each type of monocyte (Normal,
Normal + TGFβ, SSc) the expression of CXCR4 and
F-actin, particularly CXCR4, are predictive of the level of
Figure 5 Effects of TGFβ, CSD, and its subdomains on F-actin
and CXCR4 expression in normal monocytes. As described in the
Methods, normal monocytes were isolated, plated on coverslips,
treated with the indicated reagents (TGFβ, CSD, or its subdomains),
fixed, and stained for CXCR4 and F-actin and with the nuclear stain
DAPI. Representative images are shown selected from 20 to 60 cells
observed from four donors in each category. (A) Normal monocytes
treated with TGFβ and CSD; (B) Normal monocytes treated with
TGFβ and CSD subdomains. The Antennapedia Internalization
Sequence alone was routinely used as the Control peptide; when
tested scrambled CSD attached to the Antennapedia Internalization
Sequence gave similar results.
Reese et al. Respiratory Research 2013, 14:90 Page 9 of 18
http://respiratory-research.com/content/14/1/90migration. Nevertheless, CXCR4 and F-actin levels are
not sufficient to explain the different ability of each type
of monocyte to migrate strongly suggesting that CXCR4
and F-actin levels are not the only differences between
Normal, Normal + TGFβ, and SSc monocytes.
CSD and its subdomains differ in their ability to inhibit
monocyte to fibrocyte differentiation in vitro
Monocytes and monocyte-derived fibrocytes are believed
to participate in lung fibrosis both as sources of cytokines
and as the precursors of myofibroblasts [19-26]. Given that
caveolin-1 levels regulate monocyte functions, we exam-
ined the effect of CSD and it subdomains on monocyte to
fibrocyte differentiation in 12-day cultures (Figure 7). Both
CSD and Cav-BC significantly inhibited differentiation at
the routine 5 μM and even at the lowest concentration
tested (0.01 μM). In contrast, control Antennapedia pep-
tide and Cav-A had no effect at 5 μM.
When 12-day cultures were stained for collagen I
(Figure 8), we observed a similar level of staining in
normal and SSc fibrocytes which was not decreased by
CSD or Cav-BC treatment (even though these treat-
ments did decrease the number of fibrocytes present).
However, when the cultures were stained for ASMA,
we observed a high level of staining in SSc fibrocytes,
but not in normal fibrocytes, and this accumulation of
ASMA in SSc fibrocytes was almost completely blocked
by CSD or Cav-BC. During a 21-day culture, as was
shown previously [24,27], ASMA could be detected in
normal fibrocyte cultures (data not shown), indicating that
by the criterion of ASMA expression, SSc monocytes dif-
ferentiate into fibrocytes more rapidly than do normal
monocytes. The combined results highlight Cav-BC as an
excellent candidate to be a subdomain of CSD active in
the amelioration of lung fibrosis in vivo because it inhibits
profibrotic features of monocytes as well as their migra-
tion and differentiation into fibrocytes.
Dose-dependent effects of csd and subdomains on
monocyte migration
Given the Results highlighting the functional importance
of Cav-A and Cav-BC, we examined the dose-dependence
Figure 6 Effects of CSD and its subdomains on F-actin and
CXCR4 expression in SSc monocytes. As described in the
Methods, SSc monocytes were isolated, plated on coverslips, treated
with the indicated reagents (CSD or its subdomains), fixed, and
stained for CXCR4 and F-actin and with the nuclear stain DAPI. The
Antennapedia Internalization Sequence alone was routinely used as
the Control peptide; when tested scrambled CSD attached to the
Antennapedia Internalization Sequence gave similar results.
Representative images are shown selected from 20 to 60 cells
observed from four donors in each category.
Figure 7 Different effects of CSD and its subdomains on
fibrocyte differentiation. PBMC were incubated for fibrocyte
differentiation in vitro as described in the Methods in the presence
of the indicated peptides at the indicated concentrations. The
number of cells per field identified as fibrocytes by their spindle-
shaped morphology was quantified. The Antennapedia
Internalization Sequence alone was routinely used as the Control
peptide; when tested scrambled CSD attached to the Antennapedia
Internalization Sequence gave similar results. These data represent
the average ± s.e.m. of six independent fields for each condition
from five normal and five SSc donors. For comparisons of CSD and
Cav-BC with Control peptide ** indicates p < 0.01 and * indicates
p < 0.05. For Normal cells/Control peptide vs SSc cells/Control
peptide p < 0.01.
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mal monocytes with and without TGFβ treatment
(Figure 9). Even when diluted an additional 500-fold
(to 0.01 μM), CSD, Cav-A, and Cav-BC strongly inhibited
the migration of TGFβ-activated normal monocytes. For
unactivated normal monocytes, throughout the dose curve
CSD inhibited migration while Cav-A promoted migration
and Cav-BC slightly promoted migration.
CSD and its subdomains differ in their ability to inhibit
collagen I and ASMA expression and MEK/ERK signaling
in NLF and SLF
As in our previous studies, CSD inhibited collagen I
expression in both NLF and SLF, but inhibited ASMAexpression only in SLF. Cav-C, Cav-AB, and Cav-BC
inhibited collagen I expression in both cell types
(Figure 10AB) with Cav-BC being most effective, but
had different effects on ASMA expression. In particular,
Cav-C was similar to CSD in inhibiting ASMA expres-
sion in only SLF, Cav-BC inhibited ASMA expression in
both cell types, while Cav-AB did not affect either cell
type (Figure 10AB). Cav-A and Cav-B did not inhibit
collagen I or ASMA expression. In fact, Cav-A clearly
increased collagen I expression in SLF and slightly in-
creased collagen I expression in NLF. As we previously
demonstrated that MEK/ERK signaling regulates colla-
gen I and ASMA expression [2,7], we determined the ef-
fect of CSD subdomains on the activation of these
kinases. Cav-BC (like CSD) inhibited MEK and ERK ac-
tivation in both cell types (Figure 10AB). Cav-C was
somewhat less effective but still inhibited MEK and ERK
in both cell types. Cav-AB slightly inhibited MEK in
NLF and ERK in both NLF and SLF, while Cav-A and
Cav-B were inactive.
To validate these observations and to learn more
about the distribution of ASMA and activated ERK, we
examined their expression and distribution by fluores-
cent microscopy (Figure 10CD). For ASMA (Figure 10C),
as in Figure 10AB, CSD inhibited its expression only in
SLF while Cav-BC inhibited its expression in both cell
types. For activated ERK (Figure 10D), as in Figure 10AB,
inhibition of expression by CSD, Cav-BC, and Cav-C was
Figure 8 ASMA staining is observed in SSc fibrocytes, but not
normal fibrocytes, and is blocked by CSD and Cav-BC. PBMC
were incubated for fibrocyte differentiation in vitro on coverslips as
described in the Methods in the presence of the indicated peptides
at 0.1 μM, then stained for collagen I and ASMA and counterstained
with the nuclear stain DAPI. The Antennapedia Internalization
Sequence alone was routinely used as the Control peptide; when
tested scrambled CSD attached to the Antennapedia Internalization
Sequence gave similar results. Note the increased number of
fibrocytes in SSc cultures, the inhibition of fibrocyte differentiation
by CSD and Cav-BC in both SSc and normal cultures, the expression
of ASMA in SSc fibrocytes but not in normal fibrocytes, the
inhibition of ASMA expression by CSD and Cav-BC, and the similar
levels of collagen I expression in fibrocytes in all cases. Similar results
were obtained in four independent experiments.
Figure 9 Dose dependence of effects of CSD and its subdomains
on the migration in vitro of Normal monocytes with and without
TGFβ activation. The migration toward CXCL12 of Normal monocytes
with and without TGFβ activation was quantified as described in the
Methods in the presence of the indicated concentration of CSD and its
subdomains. The Antennapedia Internalization Sequence alone was
routinely used as the Control peptide; when tested scrambled CSD
attached to the Antennapedia Internalization Sequence gave similar
results. The results represent the average ± s.e.m of four independent
experiments. For comparisons of CSD, Cav-A, and Cav-BC with Control
peptide ** indicates p < 0.01 and * indicates p < 0.05. For Normal cells/
Control peptide vs TGFβ cells/Control peptide p < 0.001.
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for Cav-AB could not be detected by fluorescent micros-
copy. In addition, fluorescent microscopy revealed a
change in subcellular distribution induced by Cav-A and,
to a lesser extent, Cav-AB. Cav-A and Cav-AB caused ac-
tivated ERK to translocate to the nucleus in NLF, but not
in SLF.
To further study the effects of CSD, Cav-BC, and
Cav-C, we determined the dose-dependence of their ef-
fects on the expression of collagen I, ASMA, activated
ERK, and activated MEK in NLF and SLF (Figure 11). In
general, the effects that we observed using 5 μM peptide
(Figure 10) were almost absent at 1 μM. These experi-
ments validated the observation that CSD and Cav-C
block ASMA expression in SLF but not in NLF because
this effect was observed in cells treated with both 3 and5 μM peptide (Figure 11). In contrast, Cav-BC inhibited
ASMA expression similarly in both cell types at all con-
centrations tested.
Given that CSD and related peptides must be used at
3 μM to affect fibroblast function but strongly affect
monocyte function at 0.01 μM, we hypothesized that this
effect results from a much lower caveolin-1 concentra-
tion in monocytes than in fibroblasts. Thus proportion-
ally lower concentrations of peptide would be needed to
reverse the effects of low caveolin-1 in SSc monocytes
compared to SSc fibroblasts. To test this hypothesis, we
compared the levels of caveolin-1 in normal monocytes,
fibroblasts, and endothelial cells. Endothelial cells were
included because the literature [12] shows that, like fibro-
blasts, micromolar CSD is required to affect the function
of these cells. As predicted, the level of caveolin-1 is far
less in monocytes than in either fibroblasts or endothelial
cells (Figure 12), strongly supporting the idea that the ex-
treme sensitivity of monocytes to CSD is due to the low
baseline concentration of caveolin-1 in these cells.
Specific amino acids involved in the function of CSD
Alanine screening revealed that amino acids 90 to 92 of
caveolin-1 (particularly 92) are critical amino acids in
CSD in the regulation of eNOS-dependent NO release
from endothelial cells (Bernatchez, 2005). To determine
whether these same amino acids are critical in the ability
of CSD to regulate monocyte migration and differen-
tiation and to regulate collagen I, pERK, pMEK, and
Figure 10 Inhibition of collagen I and ASMA expression and MEK/ERK activation in fibroblasts by CSD and its subdomains. Serum-
starved NLF and SLF were incubated for an additional 6 h in fresh serum-free medium containing 5 μM of either CSD, Control peptide, or the
indicated subdomain of CSD. The Antennapedia Internalization Sequence alone was routinely used as the Control peptide; when tested
scrambled CSD attached to the Antennapedia Internalization Sequence gave similar results. The levels of collagen I in the culture medium and of
pMEK, MEK, pERK, ERK, ASMA, and actin (loading control) in the cell layer were determined by Western blotting as described in the Methods (A).
(B) Densitometric quantification combining data from three experiments similar to A performed with three independent pairs of NLF and SLF.
For comparisons of CSD and related peptides with Control peptide*** indicates p < 0.001, ** indicates p < 0.01, and * indicates p < 0.05. For NLF/
Control peptide vs SLF/Control peptide for each chart in (B) p < 0.01. Immunofluorescent detection of effects of CSD and its subdomains on pERK
(C) and ASMA (D) expression in NLF and SLF. Cells were cultured on coverslips under the conditions described above, then fixed and stained to
detect the indicated proteins. Nuclei were counterstained with DAPI.
Figure 11 Dose-dependence of inhibition of collagen I and ASMA expression and MEK/ERK activation in fibroblasts by CSD and its
subdomains. NLF and SLF were cultured as described in Figure 8 with 0, 1, 3, or 5 μM of the indicated peptides. Collagen I in the medium and
pERK, ph-MEK, ASMA and actin (loading control) in the cell layer were detected by Western blotting. Blots were quantified densitometrically. The
levels of collagen I, pERK, pMEK, and ASMA in cells treated with no peptide (divided by the level of actin) were set to 100 arbitrary units. The data
presented are the average of the densitometric quantification of three independent experiments.
Reese et al. Respiratory Research 2013, 14:90 Page 12 of 18
http://respiratory-research.com/content/14/1/90
Figure 12 Monocytes contain little caveolin-1 compared to
fibroblasts and endothelial cells. Human umbilical vein
endothelial cells (Endo), NLF (Fib), and Normal monocytes (Mono)
were extracted using SDS-PAGE sample buffer. (A) 10 μg each Endo
and Fib extract and 30 μg Mono extract were Western blotted for
caveolin-1 and actin (loading control). Similar results were obtained
when GAPDH was used as the loading control (not shown).
(B) Three times as much of each sample was loaded to allow the
detection of caveolin-1 in Mono.
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ities of CSD and the mutated versions of CSD described
as 92A and 90-92A.
Compared to CSD, both 92A and 90-92A were par-
tially active in their ability to inhibit the migration of
TGFβ-treated Normal monocytes and in their ability to
inhibit the differentiation of Normal monocytes into
fibrocytes (Figure 13AB). Although CSD inhibits the mi-
gration of Normal monocytes that had not been treated
with TGFβ, 92A and 90-92A had no effect on these
poorly migrating cells.
A range of outcomes were observed with fibroblasts
depending on the target protein and whether NLF or
SLF were being studied (Figure 13C-G). 92A and 90-
92A were fully as active as CSD in inhibiting collagen I
expression in both NLF and SLF and in inhibiting pMEK
and pERK in NLF. In contrast, 92A and 90-92A were in-
active compared to CSD in inhibiting pMEK, pERK, and
ASMA expression in SLF. None of CSD, 92A, or 90-92A
inhibited ASMA expression in NLF (i.e. cells whose
baseline expression of ASMA is low). Thus, just as the
relative activities of Cav-A, Cav-B, Cav-C, Cav-AB, and
Cav-BC are context dependent, the importance of amino
acids 90 to 92 in the regulation of cell behavior is also
context dependent in that it depends on the cell type
and readout being studied.Discussion
In this study, we have examined cellular mechanisms in-
volved in lung fibrosis that are affected when the defi-
ciency of caveolin-1 in fibrotic lung tissue is reversed
using specific subdomains of the CSD peptide and mu-
tated versions of the CSD peptide. These critical cellular
mechanisms are the migration of monocytes into dam-
aged tissue and their differentiation into fibrocytes and
the expression of collagen I by fibroblasts. Studies on
downstream molecular mechanisms through which these
versions of CSD mediate their effects are also presen-
ted. More detailed studies on molecular mechanism
are underway.
We previously showed that monocytes and fibroblasts
from SSc patients are deficient in caveolin-1, and that
treatment of these cells with the CSD peptide compen-
sates for this deficiency thereby reversing a number of
pathological features of these cells. Our goal in this
study was to determine whether different subdomains of
CSD have different abilities to regulate parameters asso-
ciated with fibrosis in monocytes and fibroblasts with
the idea that a particular subdomain might be a more ef-
fective treatment for SSc than full-length CSD. Our re-
sults are summarized in Table 4.
Migration toward CXCL12 is enhanced several-fold in
TGFβ-treated normal monocytes and even more in SSc
monocytes [17]. While CSD inhibits migration in all
three cell populations and at very low doses, the
subdomains have different effects (Table 4). Cav-BC also
strongly inhibits at very low doses the migration of cells
that migrate well (TGFβ-treated and SSc monocytes).
Lesser inhibition of migration in TGFβ-treated monocytes
was obtained with the other subdomains while Cav-A
slightly enhanced SSc monocyte migration. Cav-A, and
other subdomains to a lesser extent, also enhanced the
migration of normal monocytes (i.e. not TGFβ-treated).
Because TGFβ treatment strongly enhanced monocyte
migration, we also examined canonical TGFβ signaling
via Smad 2/3. In many cases, the effects of CSD and its
subdomains on monocyte migration and Smad 2/3 acti-
vation were similar. For example, CSD and Cav-BC
strongly inhibit the migration of monocytes that migrate
well (i.e. TGFβ-treated Normal monocytes and SSc
monocytes) and also strongly inhibit Smad 2/3 activation
in these cells. Likewise, the enhancement of migration
that occurs in Normal monocytes treated with Cav-A
was accompanied by an enhancement of Smad 2/3 acti-
vation in these cells. In other cases, the effects of
subdomains on migration and Smad 2/3 activation were
not similar. For example, several subdomains inhibited
migration in TGFβ-treated Normal monocytes without
affecting Smad 2/3 activation; several subdomains en-
hanced migration in Normal monocytes while inhibiting
Smad 2/3 activation. An additional striking observation
Figure 13 Effects of mutated CSD on monocyte and fibroblast functions. The activity of CSD and mutated forms (92A and 90-92A) were
compared. (A,B) Monocytes. (C-F) Fibroblasts. (A) Monocyte migration experiments were performed with Normal monocytes and TGFβ-treated
Normal monocytes and the indicated peptides (0.1 μM) as described in the Methods. Indication of statistical significance for TGFβ-treated Normal
monocytes with Control peptide is versus Normal monocytes with Control peptide. Indications of statistical significance for TGFβ-treated Normal
monocytes treated with CSD, 92A, or 90-92A is versus TGFβ-treated Normal monocytes treated with Control peptide. (B) Fibrocyte differentiation
experiments were performed with Normal monocytes and the indicated peptides (0.1 μM) as described in the Methods. (C) The levels of
collagen I in the culture medium and of pMEK, pERK, ASMA, and actin (loading control) in the cell layer were determined by Western blotting as
described in the Methods using NLF and SLF treated with the indicated peptides as described in the legend to Figure 10. (D-G) Densitometric
quantification combining data from three experiments similar to (C) performed with three independent pairs of NLF and SLF. (D) Collagen I.
(E) pMEK. (F) pERK. (G) ASMA. Indications of statistical significance for SLF plus Control peptide are versus NLF plus Control peptide. Indications of
statistical significance for NLF plus 92A, 90-92A, or CSD are versus NLF plus Control peptide. Indications of statistical significance for SLF plus 92A,
90-92A, or CSD are versus SLF plus Control peptide.
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activated Smad 2/3 are very high in SSc monocytes com-
pared to Normal monocytes, the enhancement in the
level of total Smad 2/3 is even more pronounced. In
summary, we find that while CSD and its subdomains
can affect TGFβ signaling via pSmad 2/3, it is likely that
their effects on TGFβ signaling combine with their well-known effects on other signaling cascades to regulate
monocyte migration.
We report here the novel observation that the differ-
entiation of SSc monocytes into spindle-shaped, ASMA-
positive, collagen I-positive fibrocytes is enhanced
compared to normal monocytes (Figure 9). In both cell
types CSD and Cav-BC inhibit monocyte differentiation at
Table 4 Differential effects of CSD subdomains on monocyte CXCR4 and F-actin expression
Cells Peptide CXCR4 Statistical significance F-actin Statistical significance
Normal Control 23.2 ± 0.8 32.1 ± 2.6
Normal CSD 20.6 ± 1.8 26.8 ± 1.7
Normal Cav-A 40.6 ± 1.9 p < 0.01 vs Normal/Control 85.8 ± 3.6 p < 0.01 vs Normal/Control
Normal Cav-B 34.6 ± 1.2 p < 0.01 vs Normal/Control 93.9 ± 2.2 p < 0.01 vs Normal/Control
Normal Cav-C 28.7 ± 0.8 p < 0.01 vs Normal/Control 73.7 ± 5.0 p < 0.01 vs Normal/Control
Normal Cav-AB 23.9 ± 0.8 42.0 ± 2.1 p < 0.05 vs Normal/Control
Normal Cav-BC 20.9 ± 0.7 34.5 ± 1.4
Normal + TGFβ Control 50.1 ± 2.6 p < 0.01 vs Normal/Control 40.7 ± 1.4 p < 0.05 vs Normal/Control
Normal + TGFβ CSD 23.7 ± 0.8 p < 0.01 vs Normal + TGFβ/Control 35.4 ± 2.0 p < 0.05 vs Normal + TGFβ/Control
Normal + TGFβ Cav-A 21.9 ± 0.6 p < 0.01 vs Normal + TGFβ/Control 49.0 ± 3.6
Normal + TGFβ Cav-B 32.4 ± 1.1 p < 0.01 vs Normal + TGFβ/Control 75.2 ± 3.7 p < 0.01 vs Normal + TGFβ/Control
Normal + TGFβ Cav-C 27.6 ± 0.8 p < 0.01 vs Normal + TGFβ/Control 54.7 ± 4.5 p < 0.01 vs Normal + TGFβ/Control
Normal + TGFβ Cav-AB 22.3 ± 0.6 p < 0.01 vs Normal + TGFβ/Control 47.5 ± 4.7
Normal + TGFβ Cav-BC 20.4 ± 0.8 p < 0.01 vs Normal + TGFβ/Control 38.7 ± 1.6
SSc Control 43.8 ± 2.6 p < 0.01 vs Normal/Control 129.2 ± 11.9 p < 0.01 vs Normal/Control
SSc CSD 27.6 ± 1.4 p < 0.01 vs SSc/Control 58.3 ± 2.8 p < 0.01 vs SSc/Control
SSc Cav-A 51.4 ± 2.6 138.1 ± 7.3
SSc Cav-B 32.6 ± 1.6 p < 0.01 vs SSc/Control 60.9 ± 5.7 p < 0.01 vs SSc/Control
SSc Cav-C 31.5 ± 1.5 p < 0.01 vs SSc/Control 100.0 ± 8.6
SSc Cav-AB 30.9 ± 2.3 p < 0.01 vs SSc/Control 79.5 ± 5.1 p < 0.01 vs SSc/Control
SSc Cav-BC 27.7 ± 0.8 p < 0.01 vs SSc/Control 92.9 ± 4.5 p < 0.05 vs SSc/Control
Image analyses of Figures 5 and 6 are quantified in terms of average fluorescence intensity ± s.e.m. and the statistical significance of the indicated comparisons
determined using Students’ t test.
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dose (Figure 9, Table 4). In summary, Cav-BC and Cav-A
are of particular interest. Cav-BC, like CSD, inhibits the
pathological hypermigration of TGFβ-treated and SSc
monocytes and the differentiation into fibrocytes of both
Normal and SSc monocytes. Unlike CSD, Cav-BC does
not inhibit the migration of Normal monocytes. Cav-A
enhances the migration of both Normal and SSc mono-
cytes although it partially inhibits the migration of TGFβ-
treated monocytes and has no effect on differentiation.
We previously reported that collagen I expression and
MEK/ERK signaling in fibroblasts (both NLF and SLF) is
inhibited by CSD but that ASMA expression is only
inhibited by CSD in cells expressing it at high levels (i.e.
SLF) [2]. Here we report that Cav-BC, like CSD, inhibits
collagen I expression and MEK/ERK signaling in both
NLF and SLF. However, unlike CSD, Cav-BC also in-
hibits ASMA expression in both cell types. The function
of Cav-A in fibroblasts is also noteworthy, causing an in-
crease in collagen I expression in SLF, a slight increase
in collagen I in NLF, and the nuclear translocation of
ERK in NLF. Thus, in both monocytes and fibroblasts
Cav-BC is the subdomain most similar in function to
CSD while Cav-A has a variety of distinct, potentially
pro-fibrotic, functions. In addition to the differencesbetween the effect of each peptide on the expression of
collagen I and ASMA and the differences between NLF
and SLF in their response to a given peptide, our results
were also very different than those of Bernatchez et al.
[11] who examined the sensitivity of eNOS activity in
endothelial cells to these same peptides. As shown in
Table 4, eNOS activity was most strongly inhibited by
intact CSD and Cav-B and was also inhibited by Cav-AB
and Cav-BC. Therefore, Table 4 demonstrates that the
ability of each peptide to regulate the expression of a
particular target protein depends on the target protein
and on the cell type being studied.
To further explore differences between particular cell
types and particular target proteins in terms of how they
are affected by different versions of CSD, we studied two
mutated versions of CSD (92A and 90-92A) that were
previously shown to be totally ineffective in inhibiting
eNOS-mediated generation of NO in endothelial cells
[11]. In contrast, 92A and 90-92A were partially active
in inhibiting monocyte migration or differentiation into
fibrocytes. Moreover, 92A and 90-92A were essentially
as effective as CSD in inhibiting Collagen I expression in
NLF and SLF and in inhibiting MEK and ERK activation
in NLF. In contrast, they were almost inactive in inhibiting
MEK and ERK activation and ASMA expression in SLF.
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the ability of versions of CSD to regulate the expression of
a particular target protein depends on the target protein
and on the cell type being studied.
Table 3 allows us to speculate on whether CSD and its
subdomains regulate monocyte migration through their
effects on CXCR4 or F-actin expression. Our observa-
tions can be summarized as: 1) The enhanced migration
of TGFβ-treated normal monocytes is correlated primar-
ily with increased CXCR4 expression while the enhanced
migration of SSc monocytes is correlated both with en-
hanced CXCR4 and F-actin expression; 2) For each type
of monocyte (Normal, Normal + TGFβ, SSc), CSD and it
subdomains had essentially parallel effects on migration
and CXCR4 expression; 3) In cells that migrate well
(Normal + TGFβ and SSc monocytes), Cav-BC and
CSD are the most effective inhibitors of migration due
to their inhibition of CXCR4 expression. In contrast,
TGFβ-treated and SSc monocytes differ greatly in that
Cav-A inhibits CXCR4 expression and migration in
TGFβ-treated monocytes while having no effect on these
parameters in SSc monocytes; 4) In cells that do not
migrate well (Normal monocytes), Cav-A promotes
migration due to its positive effects on both CXCR4 and
F-actin levels. 5) A comparison of the data obtained with
various combinations of cell type and peptide makes it
clear that other factors besides CXCR4 and F-actin
expression control migration. For example, levels of
CXCR4 and F-actin in SSc monocytes in the presence of
Cav-BC are similar to their levels in Normal monocytes
in the presence of Cav-B yet the SSc monocytes exhibit
four-fold higher migration than the Normal monocytes.
Thus, the enhanced migration of SSc monocytes com-
pared to Normal monocytes must involve more differ-
ences between these cell types than simply their CXCR4
and F-actin levels.
These studies have revealed that monocytes are much
more sensitive to CSD and its subdomains than areTable 5 Differential effects of CSD subdomains on monocyte
collagen and ASMA expression
Peptide Monoycte migration Fibrocyte differentiation
Normal TGFβ SSc Normal SSc C
Control 20.1 99.9 303 30 54
CSD ↓ ↓↓ ↓↓ ↓ ↓
Cav-A ↑↑ ↓ No Effect No Effect No Effect
Cav-B ↑ ↓ Not Done Not Done Not Done
Cav-C ↑ ↓ Not Done Not Done Not Done
Cav-AB ↑ ↓ Not Done Not Done Not Done
Cav-BC ↑ ↓↓ ↓ ↓ ↓
The Control Peptide row shows the baseline values for each cell type for Monocyte
(in Elongated cells/field from Figure 7), and for Protein Expression in Fibroblasts (in
from ref. [11]. The other rows show increases and decreases from these baseline lev
increase, No Effect = 35% decrease to 35% increase, ↓ = 35 to 65% decrease, ↓↓ = 65fibroblasts. In studies using fibroblasts [2] and endothe-
lial cells [11], 5 to 10 μM CSD was used to compensate
for a loss of caveolin-1. The current studies demonstrate
that for fibroblasts this level of CSD and subdomains is
required, because little or no effect is observed at 1 μM.
In contrast, in experiments using monocytes, we report
that CSD and Cav-BC are as active at 0.01 μM as they
are at 5 μM. These observations raise the possibility that
monocytes are more sensitive to CSD and its subdo-
mains than are fibroblasts and endothelial cells because
the baseline level of caveolin-1 in monocytes is much
lower than in these other cell types. Indeed, we have
demonstrated in Figure 12 that this is the case. This
further suggests that while the use of CSD or its
subdomains may have a therapeutic effect in human pa-
tients by reversing the profibrotic and proinflammatory
effects of low caveolin-1 in monocytes and fibrocytes,
CSD and subdomains may not have side effects in fibro-
blasts and endothelial cells because the small increase in
caveolin-1 function in these cells that already contain
caveolin-1 at high levels is not likely to have an appre-
ciable effect on their function.
Although many authors have proposed that TGFβ is
the major cytokine responsible for the pathology of SSc
and have used TGFβ-treated cells as a model for SSc,
the current results demonstrate both differences and
similarities between SSc and Normal + TGFβ monocytes
(Tables 3, 4, and 5). These observations suggest that
pathways other than TGFβ are involved in the path-
ology of SSc and that the sensitivity of these pathways to
CSD and to its subdomains differ. Therefore, it is not
surprising, for example, that Cav-A inhibits the migra-
tion of Normal + TGFβ monocytes, but slightly enhances
the migration of Normal and SSc monocytes.
Conclusions
These studies have revealed Cav-BC to be an anti-
inflammatory, anti-fibrotic subdomain of CSD that maymigration, fibrocyte differentiation, and fibroblast
Protein expression in fibroblasts and endothelial cells
ollagen NLF Collagen SLF ASMA NLF ASMA SLF eNOS End
100 200 100 260
↓↓ ↓↓ No Effect ↓↓ ↓
No Effect ↑ No Effect No Effect No Effect
No Effect No Effect No Effect No Effect ↓
↓ ↓↓ No Effect ↓ No Effect
↓↓ ↓↓ No Effect No Effect ↓
↓↓ ↓↓ ↓↓ ↓↓ ↓
Migration (in Cells/hpf from Figure 2 and Table 3), for Fibrocyte Differentiation
Arbitrary Units from Figure 10). eNOS expression in Endothelial Cell data are
els caused by CSD and related peptides (↑↑ = > 100% increase, ↑ = 35 to 100%
to 100% decrease.
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tients. In contrast, Cav-A has certain pro-inflammatory,
pro-fibrotic functions which may make it a useful treat-
ment for other diseases such as wound healing. These
studies have also revealed major differences between
Normal monocytes activated with TGFβ and SSc mono-
cytes that suggest that the pathology of this disease is more
complex than simply hyperactivated TGFβ signaling. Fu-
ture studies will expand upon the peptide-specific and cell
type-specific differences in signal transduction already
observed that must underlie these complex observa-
tions. Finally, we observed that monocytes are much more
sensitive to CSD and its subdomains than are fibroblasts,
suggesting that in vivo monocytes and fibrocytes will be
selectively affected by CSD treatment without the treat-
ment having significant side effects on other cell types.Abbreviations
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